In accordance with available evidence-based medicine, one of the ACR recommendations is that in JIA patients with active chronic anterior uveitis who have failed a first anti-TNF monoclonal antibody at an above-standard dose and/or frequency, changing to another anti-TNF monoclonal antibody is conditionally recommended over a biologic in another category [7]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.